J 2017

Intravenous thrombolysis for ischemic stroke in the golden hour: propensity-matched analysis from the SITS-EAST registry

TSIVGOULIS, G., A.H. KATSANOS, P. KADLECOVA, A. CZLONKOWSKA, A. KOBAYASHI et. al.

Základní údaje

Originální název

Intravenous thrombolysis for ischemic stroke in the golden hour: propensity-matched analysis from the SITS-EAST registry

Autoři

TSIVGOULIS, G. (300 Řecko), A.H. KATSANOS (300 Řecko), P. KADLECOVA (203 Česká republika), A. CZLONKOWSKA (616 Polsko), A. KOBAYASHI (616 Polsko), M. BROZMAN (703 Slovensko), V. SVIGELJ (705 Slovinsko), L. CSIBA (348 Maďarsko), K. FEKETE (233 Estonsko), J. KORV (233 Estonsko), V. DEMARIN (191 Chorvatsko), A. VILIONSKIS (440 Litva), D. JATUZIS (440 Litva), Y. KRESPI (792 Turecko), C. LIANTINIOTI (300 Řecko), S. GIANNOPOULOS (300 Řecko) a Robert MIKULÍK (203 Česká republika, garant, domácí)

Vydání

European Journal of Neurology, HEIDELBERG, SPRINGER HEIDELBERG, 2017, 0340-5354

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30210 Clinical neurology

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.783

Kód RIV

RIV/00216224:14110/17:00100262

Organizační jednotka

Lékařská fakulta

UT WoS

000400617200011

Klíčová slova anglicky

Intravenous thrombolysis; Acute ischemic stroke; Golden hour; Onset-to-treatment time; Mobile stroke unit

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 26. 4. 2018 10:38, Soňa Böhmová

Anotace

V originále

As there are scarce data regarding the outcomes of acute ischemic stroke (AIS) patients treated with intravenous thrombolysis (IVT) within 60 min from symptom onset ("golden hour"), we sought to compare outcomes between AIS patients treated within [GH(+)] and outside [GH(-)] the "golden hour" by analyzing propensity score matched data from the SITS-EAST registry. Clinical recovery (CR) at 2 and 24 h was defined as a reduction of ae10 points on NIHSS-score or a total NIHSS-score of ae3 at 2 and 24 h, respectively. A relative reduction in NIHSS-score of ae40% at 2 h was considered predictive of complete recanalization (CREC). Symptomatic intracranial hemorrhage (sICH) was defined using SITS-MOST criteria. Favorable functional outcome (FFO) was defined as a mRS-score of 0-1 at 3 months. Out of 19,077 IVT-treated AIS patients, 71 GH(+) patients were matched to 6882 GH(-) patients, with no differences in baseline characteristics (p > 0.1). GH(+) had higher rates of CR at 2 (31.0 vs. 12.4%; p < 0.001) and 24 h (41 vs. 27%; p = 0.010), CREC at 2 h (39 vs. 21%; p < 0.001) and FFO (46.5 vs. 34.0%; p = 0.028) at 3 months. The rates of sICH and 3-month mortality did not differ (p > 0.2) between the two groups. GH(+) was associated with 2-h CR (OR: 5.34; 95% CI 2.53-11.03) and CREC (OR: 2.38; 95% CI 1.38-4.09), 24-h CR (OR: 1.88; 95% CI 1.08-3.26) and 3-month FFO (OR: 2.02; 95% CI 1.15-3.54) in multivariable logistic regression models adjusting for potential confounders. In conclusion, AIS treated with IVT within the GH seems to have substantially higher odds of early neurological recovery, CREC, 3-month FFO and functional improvement.